| First Author | Lutz C | Year | 2020 |
| Journal | Hum Genomics | Volume | 14 |
| Issue | 1 | Pages | 20 |
| PubMed ID | 32498696 | Mgi Jnum | J:288402 |
| Mgi Id | MGI:6432686 | Doi | 10.1186/s40246-020-00272-6 |
| Citation | Lutz C, et al. (2020) COVID-19 preclinical models: human angiotensin-converting enzyme 2 transgenic mice. Hum Genomics 14(1):20 |
| abstractText | Coronavirus disease 2019 (COVID-19) is a declared pandemic that is spreading all over the world at a dreadfully fast rate. Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the pathogen of COVID-19, infects the human body using angiotensin-converting enzyme 2 (ACE2) as a receptor identical to the severe acute respiratory syndrome (SARS) pandemic that occurred in 2002-2003. SARS-CoV-2 has a higher binding affinity to human ACE2 than to that of other species. Animal models that mimic the human disease are highly essential to develop therapeutics and vaccines against COVID-19. Here, we review transgenic mice that express human ACE2 in the airway and other epithelia and have shown to develop a rapidly lethal infection after intranasal inoculation with SARS-CoV, the pathogen of SARS. This literature review aims to present the importance of utilizing the human ACE2 transgenic mouse model to better understand the pathogenesis of COVID-19 and develop both therapeutics and vaccines. |
